Paul Bisaro

Paul M.
Bisaro is currently an Independent Director at Myriad Genetics, Inc. since 2022, an Independent Director at Zoetis, Inc. since 2015, a Director at Anda, Inc., a Director at PleoPharma, Inc., and a Member of the Visitors Board at Columbus School of Law since 2014.
Former roles include Chairman, President & Chief Executive Officer at Actavis, Inc. from 2013 to 2014; President, Chief Executive Officer & Director at Impax Laboratories LLC from 2016 to 2018; President & Chief Executive Officer at Warner Chilcott Plc from 2013 to 2014; Executive Chairman at Forest Laboratories, Inc.; Chairman at Keenova Therapeutics PLC from 2022 to 2023; Chairman at Association for Accessible Medicines from 2009 to 2011; Executive Chairman at Amneal Intermediate, Inc. from 2018 to 2019; Independent Director at Zimmer Biomet Holdings, Inc. from 2013 to 2017; President, Chief Operating Officer & Director at Barr Pharmaceuticals, Inc. from 1999 to 2007; Director at Allergan UC from 2016 to 2018; Independent Director at TherapeuticsMD, Inc. from 2020 to 2022; Director at Zimmer US, Inc.; President at Teva Women's Health, Inc.; Senior Consultant at Arthur Andersen LLP; Associate at Winston & Strawn LLP from 1989 to 1992; Associate at Bishop, Cook, Purcell & Reynolds from 1989 to 1992; and President & Chief Operating Officer at Barr Laboratories, Inc. from 1999 to 2007.
Education includes a graduate degree from The Catholic University of America conferred in 1989 and an undergraduate degree from the University of Michigan conferred in 1983.